Winkler G, Salamon F, Harmos G, Salamon D, Speer G, Szekeres O, Hajós P, Kovács M, Simon K, Cseh K
Department Int. Med., St. John's Hospital, Budapest, Hungary.
Diabetes Res Clin Pract. 1998 Dec;42(3):169-74. doi: 10.1016/s0168-8227(98)00109-0.
The role of tumor necrosis factor-alpha in insulin resistance has been studied in 59 patients with Type 2 diabetes, 28 with android type obesity and 35 healthy lean controls. Immunoreactive concentrations and bioactivity of serum tumor necrosis factor-alpha have repeatedly been determined in 8 weeks intervals for 12 months, five times per patients, by using ELISA and L929 cell cytotoxicity bioassay. Significantly higher immunoreactive tumor necrosis factor-alpha concentrations and bioactivity have been found in both, the Type 2 diabetic and obese groups as compared to the healthy persons. Tumor necrosis factor-alpha concentrations and bioactivity have showed a significant positive linear correlation with the elevated basal serum C-peptide levels and body mass indexes in both groups of patients. According to these data the cytokine might play a role in insulin resistance in obesity as well in Type 2 diabetes.
肿瘤坏死因子-α在胰岛素抵抗中的作用已在59例2型糖尿病患者、28例腹型肥胖患者和35例健康瘦人对照中进行了研究。采用酶联免疫吸附测定（ELISA）和L929细胞细胞毒性生物测定法，每隔8周对患者进行12个月的血清肿瘤坏死因子-α免疫反应浓度和生物活性测定，每位患者测定5次。与健康人相比，2型糖尿病组和肥胖组的血清肿瘤坏死因子-α免疫反应浓度和生物活性均显著升高。在两组患者中，肿瘤坏死因子-α浓度和生物活性与基础血清C肽水平升高及体重指数均呈显著正线性相关。根据这些数据，细胞因子可能在肥胖及2型糖尿病的胰岛素抵抗中发挥作用。
